Search results
Results from the WOW.Com Content Network
In 2024, the United States suffered from an "all-time high" scarcity of over three hundred different kinds of drugs and medications in healthcare and pharmacy settings, surpassing the number of drug shortages present in 2014. Drugs and medications impacted by the shortage included asthma medications, anesthesia and analgesic medications ...
- A Madison woman is now accused in connection to a 2022 drug overdose death at Waupun Correctional Institution. Court records show 37-year-old Janelle Hill is charged with first-degree reckless ...
2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, and the first treatment based on the gene-editing technology CRISPR.
Thanks to the negotiations, 15 more drugs are expected to get cheaper in 2027, “followed by another 15 drugs in 2028 and 20 more in each subsequent year.” Male cancer deaths worldwide could ...
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
The United States Centers for Disease Control and Prevention has data on drug overdose death rates and totals. Around 1,106,900 US residents died from drug overdoses from 1968 to 2020, around 932,400 from 1999 through 2020 and around 93,700 in 2020. Of every 100,000 people in 2020 in the US, drugs killed 28.
By Ahmed Aboulenein and Amina Niasse. WASHINGTON (Reuters) -More than 1 million people in the U.S. will save over $1,000 a year beginning in 2025, when an annual $2,000 cap on prescription drug ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.